Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 13;22(1):58.
doi: 10.1186/s12885-021-09109-4.

The non-fatal burden of cancer in Belgium, 2004-2019: a nationwide registry-based study

Vanessa Gorasso  1   2 , Geert Silversmit  3 , Marc Arbyn  4   5 , Astrid Cornez  4 , Robby De Pauw  4   6 , Delphine De Smedt  7 , Ian Grant  8 , Grant M A Wyper  8 , Brecht Devleesschauwer  4   9 , Niko Speybroeck  10
Affiliations

The non-fatal burden of cancer in Belgium, 2004-2019: a nationwide registry-based study

Vanessa Gorasso et al. BMC Cancer. .

Abstract

Background: The importance of assessing and monitoring the health status of a population has grown in the last decades. Consistent and high quality data on the morbidity and mortality impact of a disease represent the key element for this assessment. Being increasingly used in global and national burden of diseases (BoD) studies, the Disability-Adjusted Life Year (DALY) is an indicator that combines healthy life years lost due to living with disease (Years Lived with Disability; YLD) and due to dying prematurely (Years of Life Lost; YLL). As a step towards a comprehensive national burden of disease study, this study aims to estimate the non-fatal burden of cancer in Belgium using national data.

Methods: We estimated the Belgian cancer burden from 2004 to 2019 in terms of YLD, using national population-based cancer registry data and international disease models. We developed a microsimulation model to translate incidence- into prevalence-based estimates, and used expert elicitation to integrate the long-term impact of increased disability due to surgical treatment.

Results: The age-standardized non-fatal burden of cancer increased from 2004 to 2019 by 6 and 3% respectively for incidence- and prevalence-based YLDs. In 2019, in Belgium, breast cancer had the highest morbidity impact among women, followed by colorectal and non-melanoma skin cancer. Among men, prostate cancer had the highest morbidity impact, followed by colorectal and non-melanoma skin cancer. Between 2004 and 2019, non-melanoma skin cancer significantly increased for both sexes in terms of age-standardized incidence-based YLD per 100,000, from 49 to 111 for men and from 15 to 44 for women. Important decreases were seen for colorectal cancer for both sexes in terms of age-standardized incidence-based YLD per 100,000, from 105 to 84 for men and from 66 to 58 for women.

Conclusions: Breast and prostate cancers represent the greatest proportion of cancer morbidity, while for both sexes the morbidity burden of skin cancer has shown an important increase from 2004 onwards. Integrating the current study in the Belgian national burden of disease study will allow monitoring of the burden of cancer over time, highlighting new trends and assessing the impact of public health policies.

Keywords: Burden of disease; Cancer; Years lived with disability.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Age-standardized incidence-based YLD per 100,000 rate for all cancers in Belgium and its regions by sex
Fig. 2
Fig. 2
Age-standardized incidence rates and incidence-based YLD for top 5 cancers diagnosed in men from 2004 to 2019
Fig. 3
Fig. 3
Age-standardized incidence rates and incidence-based YLD for top 5 cancers diagnosed in women from 2004 to 2019
Fig. 4
Fig. 4
Age-standardized YLD prevalence-based YLDs per 100,000 rate for all cancers in Belgium and its regions by sex
Fig. 5
Fig. 5
Age-standardized prevalence and prevalence-based YLD for top 5 cancers diagnosed in men from 2013 to 2019
Fig. 6
Fig. 6
Age-standardized prevalence and prevalence-based YLD for top 5 cancers diagnosed in women from 2013 to 2019
See this image and copyright information in PMC

References

    1. Graham JR, Mackie C. Criteria-based resource allocation: a tool to improve public health impact. J Public Health Manag Pract. 201;22(4):E14–20. - PubMed
    1. Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, Haagsma JA, Praet N, Dorny P, et al. calculating disability-adjusted life years to quantify burden of disease. Int J Public Health 2014;59(3):565–569. - PubMed
    1. Fernández de Larrea-Baz N, Álvarez-Martín E, Morant-Ginestar C, Gènova-Maleras R, Gil Á, Pérez-Gómez B, et al. Burden of disease due to cancer in Spain. BMC Public Health. 2009;9(1):42. - PMC - PubMed
    1. Bosetti C, Traini E, Alam T, Allen CA, Carreras G, Compton K, et al. National burden of cancer in Italy, 1990–2017: a systematic analysis for the global burden of disease study 2017. Sci Rep. 2020;10(1):22099. doi: 10.1038/s41598-020-79176-3. - DOI - PMC - PubMed
    1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222. doi: 10.1016/S0140-6736(20)30925-9. - DOI - PMC - PubMed